Profiel
Dror Mevorach was the founder of Enlivex Therapeutics Ltd. (2005) as Chief Scientific & Medical Officer.
Dr. Mevorach was the founder of Enlivex Therapeutics Ltd. (2009) as Chief Scientific & Medical Officer.
Dr. Mevorach is currently the Chairman-Medicine at Hadassah University Hospital.
Dr. Mevorach holds a doctorate from Technion-Israel Institute of Technology.
Actieve functies van Dror Mevorach
| Bedrijven | Functie | Begin |
|---|---|---|
Hadassah University Hospital
Hadassah University Hospital Hospital/Nursing ManagementHealth Services Operates hospitals and universities | Corporate Officer/Principal | - |
Eerdere bekende functies van Dror Mevorach
| Bedrijven | Functie | Einde |
|---|---|---|
| ENLIVEX LTD. | Oprichter | - |
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Oprichter | - |
Opleiding van Dror Mevorach
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Technion-Israel Institute of Technology
Technion-Israel Institute of Technology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hadassah University Hospital
Hadassah University Hospital Hospital/Nursing ManagementHealth Services Operates hospitals and universities | Health Services |
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Health Technology |
Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd. BiotechnologyHealth Technology Develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions | Health Technology |
















